David Huss

David Huss, the Chief Scientific Officer at Shape Therapeutics Inc., is responsible for leading the ShapeTX Research department and overseeing a team of 60+ scientists in the discovery and development of RNA-targeted medicines. Prior to their current role, David held positions at Juno Therapeutics, Biogen, The Ohio State University Wexner Medical Center, and Eli Lilly and Company, demonstrating a strong background in research and leadership within the pharmaceutical industry. David holds a PhD in Molecular, Cellular and Developmental Biology from The Ohio State University and a Bachelor of Arts in Biology from Cedarville University.